Clinical trials: Choice Behavior
Obesity, Adolescent Obesity
Effect Of HCP On Nutrition, Physical Activity And Body Mass Index
The goal of this clinical trial is to test effectiveness of "The Healthy Choices Program, in adolescents. The main question[s] it aims to answer are: 1. Effectiveness of Healthy Choices on Body Mass Index 2.
- Trial name
- NCT06442696
- Testing
- Health Education: Healthy Choices Program
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bahçeşehir University
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
The purpose of this study is to compare the efficacy and safety of liso-cel vs Investigator's Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult participants with R/R CLL or SLL, whose disease has failed…
- Trial name
- NCT06205290
- Testing
- Liso-cel, Idelalisib, Rituximab
- Where
- 48 sites in United States, Austria and 9 more
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Cancer, Cardiovascular Diseases
ActivityChoice: Implementing Clinic-Based Physical Activity Program Choices for Cancer Survivors
Cardiovascular disease, the number one leading cause of death in the United States, is highly prevalent in cancer survivors. Physical activity can reduce risk, and referrals to programs addressing survivors' choices are highly…
- Conditions
- Cancer, Cardiovascular Diseases, Physical Inactivity
- Trial name
- NCT05870176
- Testing
- Enhanced Referral, Standard Referral
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Covid-19 Vaccination
Effect of Messaging on Pragmatic Outcomes Within an Integrated Healthcare System
COVID-19 vaccination among patients at high risk for severe disease has declined in the United States since 2022. Prior research, including discrete choice experiments (DCEs), has demonstrated that vaccine preferences are…
- Trial name
- EMPOWeR (NCT07838038)
- Testing
- Vaccine choice message, Vaccine choice + platform-framed message, Vaccine choice + HCP trust-framed message
- Where
- United States
- Volunteers
- 1,300,000 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Locally Advanced/Metastatic/Recurrent ESCC
SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma
This study is a randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Study of SYS6010 vs Investigator's Choice Single-Agent Chemotherapy in Locally Advanced/Metastatic/Recurrent ESCC Patients with Failure of At Least One Line…
- Trial name
- NCT07417735
- Testing
- SYS6010, Investigator's Choice of Chemotherapy (Irinotecan hydrochloride，Paclitaxel，Docetaxel)
- Volunteers
- 436 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Major Depressive Disorder, Neoplasms
Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer
This is a pilot study to test the hypothesis that the antidepressants mirtazapine and citalopram are effective treatment for major depressive disorder (MDD) in cancer patients.
- Trial name
- NRR (NCT01725048)
- Testing
- Mirtazapine, Citalopram
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Gastric Cancer
Evaluation of a Computer-aided Diagnosis System (CADx) in the Early Detection of Gastric Cancer in France. Cancer in France.
Upper gastrointestinal (GI) cancers are one of the most common cancers worldwide. Except for cardia cancers, the incidence of gastric cancer has decreased consistently since 1980, but remains at a high level.
- Trial name
- EGC-France (NCT05928819)
- Testing
- Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Ovarian Cancer
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
This study is a randomized, open-label, active-controlled, multicenter phase III clinical trial. It is planned to enroll 300 subjects with platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary…
- Trial name
- NCT06990503
- Testing
- SHR-A1811, Chemotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Triple-Negative Breast Cancer (TNBC)
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
- Trial name
- NCT06732323
- Testing
- ESG401, Investigator's Choice Chemotherapy
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Multiple Sclerosis
Drug Risk Aversion Calculator Use to Facilitate MS Patient Self-efficacy
The investigators seek to determine if the use of a Side Effect Aversion Calculator helps patients with multiple sclerosis (MS) more comfortably and rapidly identify the disease modifying drug (DMD) that is best suited for the…
- Trial name
- DRAC (NCT03375541)
- Testing
- Risk Aversion Calculator
- Sponsor
- Duke University
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have…
- Trial name
- NCT07139873
- Testing
- DZD8586, Bendamustine, Idelalisib
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- Dizal Pharmaceuticals
PreDiabetes
Prevention and Choice for Type 2
People living with prediabetes are advised to lose weight to prevent development of type 2 diabetes by participating in intensive lifestyle interventions (ILI's), such as PreventT2.
- Trial name
- PACT2 (NCT06377020)
- Testing
- PACT2
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Health Promotion
Effects of the Health Promotion Program on Health Literacy, Physical and Mental Health Status, and Quality of Life
This study aims to evaluate the physical and mental health status, prevalence of chronic diseases, health literacy, and health behaviors of residents in Gandaki Province, Nepal, and to assess the effectiveness of a…
- Trial name
- NCT07306520
- Testing
- Health education, Auricular acupressure, Exercise
- Where
- South Korea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Inha University Hospital
Myelofibrosis
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of…
- Trial name
- NCT04562870
- Testing
- Selinexor, Physician's Choice Treatment
- Where
- 21 sites in United States, China and 5 more
- Volunteers
- 112 people
- Sponsor
- Karyopharm Therapeutics Inc
Hypercholesterolemia
Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by a regimen of Alirocumab including a starting dose of 150 mg every 4 weeks (Q4W) as add-on to non-statin lipid modifying background…
- Trial name
- NCT02023879
- Testing
- Alirocumab, Non-statin LMT, Diet Alone
- Where
- 43 sites in United States, Australia and 6 more
- Volunteers
- 233 people
- Sponsor
- Sanofi
Triple Negative Breast Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC)…
- Trial name
- NCT05633654
- Testing
- Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine
- Where
- 376 sites in United States, Australia and 10 more
- Volunteers
- 1,514 people
- Sponsor
- Gilead Sciences
Indolent B-cell NHL
A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.
To compare the efficacy of bendamustine against treatment of physician's choice on progression-free survival in subjects with indolent B-cell NHL.
- Trial name
- ROBIN (NCT01289223)
- Testing
- Bendamustine IV, Treatment of Physicians Choice
- Where
- 3 sites in Australia, Slovakia
- Volunteers
- 88 people
- Sponsor
- Mundipharma Research Limited
Colorectal Neoplasms
CHOICE: Communicating Health Options Through Information and Cancer Education
The purpose of this study is to determine the effectiveness of a two-component intervention, that combines academic detailing at the medical practice level and distribution of decision aids at the patient level, on adherence to…
- Trial name
- NCT00134589
- Testing
- Academic Detailing (Medical Practices)+Decision Aids (Patients)
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Obesity, Food Selection
Using Single and Combined Nudge Strategies to Promote Healthier Beverage Intake Among College Students
The primary objective of this study was to examine whether three nudging strategies influence beverage consumption behavior among Chinese university students.
- Trial name
- NCT07625969
- Testing
- choice architecture
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University
Intellectual Disability, Adolescent Development
Prevention Among Young People With Intellectual Disability
This study aims to evaluate an intervention using the Toolkit "Children - what does it involve?" and the "Real-Care-Baby" (RCB) simulator among students with intellectual disability (ID), using a cluster randomized trial design…
- Conditions
- Intellectual Disability, Adolescent Development, Young Adult
- Trial name
- NCT03348124
- Testing
- "Children - what does it involve?"
- Where
- Sweden
- Volunteers
- 59 people
- Sponsor
- Uppsala University